Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11027MR)

This product GTTS-WQ11027MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2&ERBB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3; NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 2065
UniProt ID P04626; P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11027MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4743MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BPS-804
GTTS-WQ11486MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ1410MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ11459MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ8097MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ9283MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-132
GTTS-WQ14583MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ4498MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-931699
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW